Physician profile
James Peter Hansen
NPI 1720198203
$4,961.07
in general payments reported to CMS, 2019-2025
27 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $137 · 2021: $62.06 · 2022: $657 · 2023: $836 · 2024: $1,378 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $765.17 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $613.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $418.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.41 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $370.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.53 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $309.29 | 2019-2025 | Airsupra, Breztri, Wainua |
| Amgen INC. | $284.74 | 2020-2024 | Prolia, Evenity, Repatha |
| Teva Pharmaceuticals USA, INC. | $274.94 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $146.32 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $115.43 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $114.51 | 2022-2023 | Xarelto |
| Neurocrine Biosciences, INC. | $111.55 | 2023-2025 | Ingrezza |
| Emd Serono, INC. | $98.17 | 2024-2025 | |
| Bausch Health US, LLC | $90.94 | 2022-2023 | Aplenzin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $81.24 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $78.37 | 2023-2025 | Shingrix, Arexvy |
| Viiv Healthcare Company | $67.28 | 2022 | |
| Lundbeck LLC | $57.19 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $38.84 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $38.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.62 | 2024-2025 | Zoryve |
| Lexicon Pharmaceuticals, INC. | $27.23 | 2024 | |
| Gilead Sciences, INC. | $26.55 | 2025 | Yeztugo |
| Phathom Pharmaceuticals, INC. | $26.08 | 2025 | Voquezna |
| Edwards Lifesciences Corporation | $24.37 | 2024 | Sapien 3 Ultra Resilia |
| Arbor Pharmaceuticals, INC. | $20.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.